THE ROLE OF PHARMACOMETRICS IN REGULATORY SCIENCE

pre-meeting workshop for the World Conference on Pharmacometrics (WCoP)

Sunday, August 21, 2016 08:00 – 15:15
Brisbane Convention and Exhibition Centre Brisbane, Australia Meeting Room P3

Please register using the following LINK.

Meeting Topics

• Strategic ISoP/C-Path Alliance for the Advancement of Pharmacometrics and Regulatory Science
• Regulatory Science and Quantitative Drug Development Tools
• Digital Biomarkers and Quantitative Model
• Case Studies of Pharmacometrics Applied in Regulatory Science

The FDA’s Critical Path Initiative identified modeling and simulation as a priority area of active research opportunities in regulatory science. Regulatory science is now recognized as more than just developing new methods for evaluating therapeutic candidates in a more efficient manner. It requires a cultural shift relating to how drug developers, patients and regulators view the tradeoff between risk and reward. Collaboration among disciplines offers a particularly productive venue for developing a regulatory science workforce. The Coalition Against Major Diseases (CAMD) is convening a pre-meeting workshop in association with WCoP with the goals of discussing with the modeling and simulation community, the areas of cross-fertilization between pharmacometrics and regulatory science. The value proposition of quantitative drug-disease-trial models as drug development platforms will be highlighted, and case studies of the potential of novel and integrated data sources for the development of such models will be shared.

The conference agenda is available (HERE).

Klaus Romero, MD, MS, FCP
Director of Clinical Pharmacology 520.547.3440 kromero@c-path.org

Jennifer Ashley Ferstl, BA
Project Coordinator 520.382.1403 jferstl@c-path.org

Please register using the following LINK.